Paying for Mental Health Care

Why Insurance Covers Spravato but Not Ketamine Infusions

Save

The coverage split is mostly about FDA status. Spravato is an approved esketamine treatment for treatment-resistant depression, so insurers cover it under criteria. IV ketamine for depression is used off-label without that approval, so plans have generally left it uncovered — which is why it usually ends up cash-pay.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Why does one get covered and the other doesn't?

The cleanest explanation is regulatory, not medical mystery. Spravato is a form of esketamine that carries FDA approval specifically for treatment-resistant depression, and that approval gives insurers a defined basis to pay when their criteria are met 1. Intravenous ketamine used for depression is a different situation: it is given off-label, meaning for a use the FDA has not formally approved for that indication, and plans have generally responded by not covering it for depression. That is the asymmetry in one sentence — approval on one side, off-label use on the other — and it is why two treatments that sound like cousins land on opposite sides of your bill. Reading how Spravato coverage works makes the contrast concrete.

What does "off-label" actually mean for your bill?

Off-label use is common and legal in medicine, but it changes the coverage math. When a treatment lacks formal approval for the specific condition it is being used to treat, insurers often decline to pay for that use, which pushes the cost onto the patient. For depression, that is the usual position on IV ketamine: the infusions themselves are frequently offered on a cash-pay basis rather than billed to insurance. Research that compares esketamine with intravenous ketamine treats them as distinct options with distinct cost profiles, which is why you cannot assume Spravato's coverage carries over to infusions 2. The label status, more than the chemistry, is what your plan is reacting to when it says yes to one and no to the other.

Does that mean ketamine infusions are worse?

No — and it is worth separating the coverage question from a value judgment. A treatment being off-label for depression is a statement about its regulatory approval status, not a verdict on whether it can help anyone, and this page is not the place to weigh clinical outcomes. What the coverage rule reliably tells you is financial: an off-label infusion course will more often be your out-of-pocket responsibility, while an approved therapy like Spravato has a coverage pathway. Keeping those two questions apart — will my plan pay versus is this right for me clinically — keeps you from reading a denial as a medical judgment or a coverage approval as an endorsement. The clinical question belongs with your prescriber; the coverage question is the one this page can answer.

What if you're set on infusions anyway?

If IV ketamine is the path you and your clinician are considering, planning for the cash-pay reality is the practical move. Clinics offering infusions on a self-pay basis are required to give uninsured or self-pay patients a good faith estimate of expected charges before scheduled care, with a dispute process if the final bill substantially exceeds it 3. Asking for that estimate up front lets you price a full course rather than a single visit. It is also reasonable to ask whether any portion — an office visit or lab work, for instance — might be billable to insurance even when the infusion itself is not. Comparing that total against what an infusion course costs elsewhere helps you plan realistically.

When to weigh the covered path first

Because the coverage difference is so large, it is usually worth understanding the approved option before committing to a cash-pay one. Real-world data show that many patients do reach esketamine through their benefits rather than paying full price, which can make the covered route more accessible than it first appears 4. That does not mean Spravato is right for everyone — only that the coverage math often favors starting there. If you use Gale to talk with a provider, you can lay both paths side by side: what your plan would pay for the approved treatment, and what an off-label course would cost you directly. Seeing the two options compared for coverage turns an abstract asymmetry into a decision you can actually make.

Common questions

Usually because IV ketamine for depression is used off-label — for a use the FDA has not formally approved for that condition — and plans have generally declined to cover it for depression 2. Spravato, by contrast, is an FDA-approved esketamine treatment for treatment-resistant depression, which gives insurers a defined basis to pay under criteria 1.

No. Off-label describes regulatory approval status, not whether a treatment can help. Many effective treatments are used off-label. What the label status reliably predicts is coverage: an off-label use for depression is more likely to be your out-of-pocket cost. Whether infusions are right for you clinically is a question for your prescriber, not your insurer.

They are related but not interchangeable on your bill. Spravato is esketamine delivered as a nasal spray with FDA approval for treatment-resistant depression, while IV ketamine for depression is a distinct, off-label option 2. The approval difference is what drives the coverage split, so you cannot assume one's coverage applies to the other.

Sometimes portions like an office visit or lab work may be billable even when the infusion itself is not, so it is reasonable to ask the clinic. For the self-pay part, you are entitled to a good faith estimate of expected charges before scheduled care, with a dispute process if the final bill substantially exceeds it 3.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

If things feel heavy, a person is available anytime — call or text 988.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

If cost or coverage is blocking urgent care

  • —Thoughts of suicide, or of not wanting to be alive
  • —Forgoing needed treatment because covered options feel out of reach
  • —A depression that is worsening while you compare coverage paths

Coverage of ketamine infusions and Spravato depends on FDA approval status, your health plan, and your clinical situation; this article describes general patterns, not your specific policy or medical care. It is general information, not medical or insurance advice. If you are in crisis, call or text 988 (Suicide & Crisis Lifeline), free and available 24/7.

References

  1. 1.Agboola F et al. (2020). The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression. Journal of Managed Care & Specialty Pharmacy (JMCP). doi:10.18553/jmcp.2020.26.1.16 ✓esketamine-cost-effectivenessesketamine-value-assessmenticer-reporttreatment-resistant-depression-cost
  2. 2.Brendle M et al. (2022). Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates. Journal of Affective Disorders. doi:10.1016/j.jad.2022.09.083 ✓esketamine-cost-effectivenessesketamine-vs-iv-ketamineinterventional-psychiatry-cost
  3. 3.Centers for Medicare & Medicaid Services (2022). Overview of rules & fact sheets (No Surprises Act). CMS.gov (No Surprises Act). link ✓
  4. 4.Zhdanava M et al. (2023). Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States. Journal of Medical Economics. doi:10.1080/13696998.2023.2208993 ✓esketamine-coveragespravato-accessclaims-based-utilizationinterventional-access

4 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library